[ASTRO] QoQ Cumulative Quarter Result on 31-Oct-2022 [#3]

Stock
[ASTRO] ASTRO MALAYSIA HOLDINGS BERHAD
Announcement Date
15-Dec-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Jan-2023
Quarter
31-Oct-2022 [#3]
Profit Trend
QoQ- 2.92%
YoY- -38.89%
Quarter Report
Latest QR
Upcoming QR
ASTRO's Result
ASTRO's Financial Summary
View:
Show?
Cumulative Result
31/07/23 30/04/23 31/01/23 31/10/22 31/07/22 30/04/22 31/01/22 CAGR
Revenue 1,760,946 891,126 3,800,065 2,809,393 1,883,209 962,089 4,175,480 -43.85%
PBT 50,256 20,635 288,941 245,756 254,127 126,935 590,714 -80.74%
Tax -17,444 -7,549 -78,453 -52,286 -63,642 -31,163 -130,087 -73.89%
NP 32,812 13,086 210,488 193,470 190,485 95,772 460,627 -82.89%
-
NP to SH 39,546 15,895 259,038 204,285 198,484 100,018 460,878 -80.63%
-
Tax Rate 34.71% 36.58% 27.15% 21.28% 25.04% 24.55% 22.02% -
Total Cost 1,728,134 878,040 3,589,577 2,615,923 1,692,724 866,317 3,714,853 -40.04%
-
Net Worth 1,133,654 1,111,211 1,071,059 1,131,547 1,168,049 1,176,392 1,125,290 0.49%
Dividend
31/07/23 30/04/23 31/01/23 31/10/22 31/07/22 30/04/22 31/01/22 CAGR
Div 13,036 13,036 156,435 156,435 117,326 65,181 351,979 -88.95%
Div Payout % 32.97% 82.01% 60.39% 76.58% 59.11% 65.17% 76.37% -
Equity
31/07/23 30/04/23 31/01/23 31/10/22 31/07/22 30/04/22 31/01/22 CAGR
Net Worth 1,133,654 1,111,211 1,071,059 1,131,547 1,168,049 1,176,392 1,125,290 0.49%
NOSH 5,214,506 5,214,506 5,214,506 5,214,506 5,214,506 5,214,506 5,214,506 0.00%
Ratio Analysis
31/07/23 30/04/23 31/01/23 31/10/22 31/07/22 30/04/22 31/01/22 CAGR
NP Margin 1.86% 1.47% 5.54% 6.89% 10.11% 9.95% 11.03% -
ROE 3.49% 1.43% 24.19% 18.05% 16.99% 8.50% 40.96% -
Per Share
31/07/23 30/04/23 31/01/23 31/10/22 31/07/22 30/04/22 31/01/22 CAGR
RPS 33.77 17.09 72.87 53.88 36.11 18.45 80.07 -43.84%
EPS 0.76 0.30 4.98 3.92 3.81 1.92 8.84 -80.60%
DPS 0.25 0.25 3.00 3.00 2.25 1.25 6.75 -88.95%
NAPS 0.2174 0.2131 0.2054 0.217 0.224 0.2256 0.2158 0.49%
Adjusted Per Share Value based on latest NOSH - 5,214,506
31/07/23 30/04/23 31/01/23 31/10/22 31/07/22 30/04/22 31/01/22 CAGR
RPS 33.76 17.09 72.86 53.86 36.11 18.45 80.05 -43.85%
EPS 0.76 0.30 4.97 3.92 3.81 1.92 8.84 -80.60%
DPS 0.25 0.25 3.00 3.00 2.25 1.25 6.75 -88.95%
NAPS 0.2174 0.213 0.2053 0.2169 0.2239 0.2255 0.2157 0.52%
Price Multiplier on Financial Quarter End Date
31/07/23 30/04/23 31/01/23 31/10/22 31/07/22 30/04/22 31/01/22 CAGR
Date 31/07/23 28/04/23 31/01/23 31/10/22 29/07/22 29/04/22 31/01/22 -
Price 0.535 0.695 0.615 0.675 0.895 1.00 0.96 -
P/RPS 1.58 4.07 0.84 1.25 2.48 5.42 1.20 20.19%
P/EPS 70.55 228.00 12.38 17.23 23.51 52.14 10.86 249.35%
EY 1.42 0.44 8.08 5.80 4.25 1.92 9.21 -71.34%
DY 0.47 0.36 4.88 4.44 2.51 1.25 7.03 -83.60%
P/NAPS 2.46 3.26 2.99 3.11 4.00 4.43 4.45 -32.71%
Price Multiplier on Announcement Date
31/07/23 30/04/23 31/01/23 31/10/22 31/07/22 30/04/22 31/01/22 CAGR
Date 25/09/23 19/06/23 27/03/23 15/12/22 26/09/22 21/06/22 31/03/22 -
Price 0.51 0.66 0.66 0.71 0.83 0.94 1.10 -
P/RPS 1.51 3.86 0.91 1.32 2.30 5.09 1.37 6.72%
P/EPS 67.25 216.52 13.29 18.12 21.81 49.01 12.45 208.80%
EY 1.49 0.46 7.53 5.52 4.59 2.04 8.03 -67.56%
DY 0.49 0.38 4.55 4.23 2.71 1.33 6.14 -81.54%
P/NAPS 2.35 3.10 3.21 3.27 3.71 4.17 5.10 -40.42%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment